CD7 CAR-T therapy for patients with relapsed or refractory T-cell malignancies

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the safety and efficacy of autologous and donor-derived CD7 CAR T-cell therapy in patients suffering from refractory or relapsed T-cell malignancies, specifically T-cell acute lymphoblastic leukemia. The study is multi-center and open-label, involving patients who have not responded to standard treatments. Participants will receive CD7 CAR T cells based on their hematopoietic stem cell transplant history and leukemia burden. The primary objectives include assessing dose limiting toxicity and overall response rates to the treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Only patients who meet all the following criteria can be included in the group:

1. CD7-positive refractory or relapsed T-cell malignancies with progression or intolerance after all standard treatments, limited prognosis from currently available treatments and no available treatment options (e.g. HSCT or chemotherapy).
2. Tumor cells in bone marrow or cerebrospinal fluid are positive for CD7 antigen by flow cytometry or tumour tissue is positive for CD7 by immunohistochemistry (CD7 antigen positivity by flow cytometry: \>80% of tumour cells expressing CD7 with a mean fluorescence intensity \[MFI\] of CD7 similar to that of normal T cells are considered to have fully positive expression; \>80% of tumor cells expressing CD7 but with an MFI of CD7 at least 1 log lower than that of normal T cells are considered to have low expression \[dim\]; tumor cells with a CD7 expression rate between 20-80% are considered to have partial expression; CD7 antigen positivity by pathological immunohistochemistry: \>30%);
3. Male or female, age 1-70 years;
4. No severe allergic constitution;
5. Eastern Cooperative Oncology Group (ECOG) performance status score (Oken et al., 1982) of 0-2;
6. Life expectancy of at least 60 days as determined by the investigator;
7. Provide a signed informed consent form prior to any screening procedures; subjects volunteering to participate in the study should be capable of understanding and signing the informed consent form and be willing to follow the study visit schedule and associated study procedures as specified in the protocol. Subjects aged 19-70 years old need to be sufficiently aware and capable of signing the informed consent form; subjects aged 1-7 years can be recruited after legal guardians or patient advocates sign the informed consent form; subjects aged 8-18 years need to be sufficiently aware and able to sign the informed consent form, and their legal guardians or patient advocates also need to sign the informed consent form.

Exclusion Criteria:

Patients with at least one of the following conditions are excluded:

1. Intracranial hypertension or unconscious;
2. Acute heart failure or severe arrhythmia;
3. Acute respiratory failure;
4. Other types of malignant tumors;
5. Diffuse intravascular coagulation;
6. Serum creatinine and/or blood urea nitrogen over 1.5 times the normal value;
7. Sepsis or other uncontrolled infection;
8. Uncontrolled diabetes mellitus;
9. Severe psychological disorder;
10. Obvious cranial lesions by cranial MRI;
11. Allergic constitution;
12. Organ recipients;
13. Pregnant or breastfeeding;
14. Active, uncontrolled infection, including hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) or treponema pallidum (TP).

Where it's running

• Beijing GoBroad Hospital
  Beijing, Beijing Municipality, China Recruiting
• Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine
  Shanghai, Shanghai Municipality, China Recruiting
• Shanghai Liquan Hospital
  Shanghai, Shanghai Municipality, China Recruiting
• The General Hospital of Western Theater Command PLA
  Chengdu, Sichuan, China Not yet recruiting

Study contacts

• Study coordinator: zhuojun ling
• Email: lingzj@gobroadhealthcare.com
• Phone: 86+18611422920

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Nanobody CD5 CAR‑T for relapsed or refractory CD5‑positive T‑cell cancers

  This will test a CD5-targeted CAR‑T cell treatment using patients' own or donor-derived cells to try to help people with relapsed or refractory CD5+ T‑cell leukemias and lymphomas.

  Recruiting at 3 sites Phase 1/2 Beijing GoBroad Hospital · Beijing, Beijing Municipality and 3 other locations · NCT07070323

• CD5 CAR T-cell therapy for relapsed or refractory T-cell malignancies

  This study is testing a new CAR T-cell therapy for people with hard-to-treat T-cell cancers to see if it is safe and how well it works.

  Recruiting at 3 sites Phase 1/2 Beijing GoBroad Hospital · Beijing, Beijing Municipality and 3 other locations · NCT06316856

• In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma

  This early-phase trial tests a one-time in vivo CAR T-cell therapy (SL1617) for people with relapsed or refractory B-cell lymphoma to see if it is safe and tolerable.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing · NCT07775508

• Anti-CCR9 CAR T-cell therapy for T‑cell acute lymphoblastic leukaemia and lymphoblastic lymphoma

  We will try anti-CCR9 CAR T cells made from your own blood to find a dose that is safe for children and adults with relapsed or refractory T‑cell leukaemia or lymphoma.

  Recruiting Phase 1 University College, London · London · NCT07300683

• CD7 CAR T therapy for high-risk T-cell cancers

  This study tests a patient’s own edited T cells, engineered to target CD7, in people with relapsed or high-risk T-cell leukemia or lymphoma.

  Recruiting Phase 1 Baylor College of Medicine · Houston, Texas and 1 other locations · NCT07220993

• CD5 CAR T-cell therapy for relapsed or refractory T-cell lymphoma

  This trial tries CD5 CAR T-cell therapy, using either the patient's own cells or donor cells, and may bridge to stem-cell transplant for people 14–70 with relapsed or refractory T-cell lymphoma.

  Recruiting at 3 sites Phase 1/2 Beijing GoBroad Hospital · Beijing and 2 other locations · NCT07022964

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.